Figure 2. The addition of HCQ does not significantly impact the pharmacokinetic profile of VOR. (A) Quantification of whole blood concentrations of HCQ. HCQ concentrations were determined as described in Patients and Methods. HCQ levels for patients that received 400 mg and 600 mg HCQ are shown. *Indicates P < 0.05. (B) Serum concentrations of VOR. The concentrations of VOR in the serum of patients enrolled on the study were quantified as detailed in Patients and Methods. Plot shows the time dependence of serum VOR levels (concentration vs. time). Numbers indicate the subject number. Post-HCQ concentration curves are marked with a (0.1) after the patient number. (C) Comparison of VOR levels over time in specimens collected pre- and post-HCQ treatment. Pre-HCQ VOR concentrations are plotted on the left (n = 30), post-HCQ VOR levels are plotted on the right (n = 14). Wilcoxon Signed Rank testing determined that the time-dependence of VOR concentrations was not significantly affected by the addition of HCQ.